Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 2
2015 4
2016 3
2017 1
2018 3
2019 1
2020 3
2021 6
2022 2
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Tubulin inhibitors in non-small cell lung cancer: looking back and forward.
Ferrara R, Pilotto S, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E. Ferrara R, et al. Among authors: peretti u. Expert Opin Pharmacother. 2016 Jun;17(8):1113-29. doi: 10.1517/14656566.2016.1157581. Epub 2016 Mar 10. Expert Opin Pharmacother. 2016. PMID: 26898217 Review.
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S, Novello S, Peretti U, Kinspergher S, Ciuffreda L, Milella M, Carbognin L, Vavalà T, Ferrara R, Caccese M, Tortora G, Bria E. Pilotto S, et al. Among authors: peretti u. Expert Opin Investig Drugs. 2015;24(9):1143-61. doi: 10.1517/13543784.2015.1056341. Epub 2015 Jun 12. Expert Opin Investig Drugs. 2015. PMID: 26065529 Review.
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.
Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Pilotto S, et al. Among authors: peretti u. Crit Rev Oncol Hematol. 2014 May;90(2):135-45. doi: 10.1016/j.critrevonc.2013.11.005. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24332915 Review.
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C; GARIBALDI Study Group. Reni M, et al. ESMO Open. 2023 Feb;8(1):100777. doi: 10.1016/j.esmoop.2022.100777. Epub 2023 Feb 1. ESMO Open. 2023. PMID: 36731325 Free PMC article.
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM, Orsi G, Cavaliere A, Niger M, Avallone A, Salvatore L, Tortora G, Rapposelli IG, Giordano G, Noventa S, Giommoni E, Bozzarelli S, Macchini M, Peretti U, Procaccio L, Puccini A, Cascinu S, Montagna C, Milella M, Reni M. Militello AM, et al. Among authors: peretti u. Cancer Chemother Pharmacol. 2023 Dec;92(6):501-510. doi: 10.1007/s00280-023-04585-w. Epub 2023 Sep 19. Cancer Chemother Pharmacol. 2023. PMID: 37725113
28 results